

## 6. Literaturverzeichnis:

Alvir JM, Liebermann JA, Saffermann AZ, Schwimmer JL, Schaaf JA: Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. *New England Journal of Medicine* 1993;329: 162-167

Andres E, Noel E, Kurtz JE, Henoun Loukili N, Kaltenbach G, Maloisel F: Life-threatening idiosyncratic drug-induced agranulocytosis in elderly patients. *Drugs Aging* 2004;21(7):427-35.

Andrés E, Maloisel F, Kurtz JE, Kaltenbach G, Alt M: Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. *European Journal of Internal Medicine* 2002;13: 324-328

Andrés E, Kurtz JE, Perrin AE, Dufour P, Schlienger JC, Maloisel F: Hematopoietic growth factor in antithyroid-drug-induced agranulocytosis. *Q J Med* 2001;94: 423-428

Bénichou C, Solal-Celigny P: Standardization of Definitions and criteria for causality assessment of adverse drug reactions. Drug-induced blood cytopenias: report of an international consensus meeting. *Nouv Rev Fr Hematol* 1993; 33: 257-262

Benkert O, Hippus H: *Kompendium der Psychiatrischen Pharmakotherapie*. 4. Auflage, Springer Berlin 2002

Bhatt V, Saleem A: Review: Drug-induced neutropenia – pathophysiology, clinical features and management. *Annals of Clinical Laboratory Science* 2004;34(2): 131-137

Beg AA: Endogenous ligands of Toll-like-receptors: implications for regulating inflammatory and immune responses. *Trend Immunology* 2002;23:509-512

Byrd RB, Horn BR, Solomon DA, Griggs GA: Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1000 Patients. *JAMA* 1979;241:1239-1241

Bigby M: Rates of cutaneous reactions to drugs. *Archives of Dermatology* 2001;137: 765-770

Carlsson LE, Santoso S, Baurichter G, Kroll H, Papenberg S, Eichler P, Westerdal NAC, Kiefel V, van de Winkel JGJ, Greinacher A: Heparin-induced Thrombocytopenia: New Insights Into the Impact of the Fc-gammaRIIA-R-H131 Polymorphism. *Blood* 1998;92(5): 1526-1531

Claas FH, Abbott PA, Witvliet MD, D'Amaro J, Barnes PM, Krupp P.: No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. *Drug Saf* 1992;7(Suppl. 1):3-6.

Copolov DL, Bell WR, Benson WJ, Keks NA, Strazzeri DC, Johnson GF: Clozapine treatment in Australia: a review of haematological monitoring. *Medical Journal of Australia*. 1998; 168: 495-497

Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF: Inflammatory Cytokines provide a third signal for activation of naive CD4 and CD8 Cells. *J Immunology* 1999; 162:3256-3262

D'Alessandro AM, Pirsch JD, Knechtle SJ, Odorico JS, Van der Werf WJ, Collins BH, Becker YT, Kalayoglu M, Armbrust MJ, Sollinger HW. :Living unrelated renal donation: the University of Wisconsin experience. *Surgery* 199;124(4):604-10.

Dearon M: Structural basis of Fc- $\gamma$ -Receptor functions. *Int Rev Immunology* 1997;16: 1-27

Dettling M, Cascorbi I, Roots I, Mueller-Oerlinghausen B.: Genetic determinants of clozapine-induced agranulocytosis: recent results of HLA subtyping in a non-jewish caucasian sample. *Arch Gen Psychiatry* 2001;58(1):93-4.

Edwards IR, Aronson JK: Adverse Drug Reactions: definition, diagnosis, and management. *Lancet* 2000; 356:1255-1259

Einarson TR: Drug related hospital admissions. *Annals of Pharmacotherapy* 1993;27: 832-840

Evans WE, Relling MV: Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. *Science* 1999;286: 487-491

Farrel J, Naisbitt DJ, Drummond NS, Depta JPH, Vilar FJ, Pirmohamed M, Park BK: Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-specific T-cell responses in Animals and Humans. *J Pharmac Exp Therapeutics* 2003;306(1): 229-237

Fischer V, Haar JA, Greiner L, Lloyd RV, Mason RP.: Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis. *Mol Pharmacol* 1991;40(5): 846-53.

Flesch BK, Bauer F, Neppert J: Rapid typing of the human Fc-gamma-Rezeptor-Iia polymorphism by polymerase chain reaction amplification with allele-specific primers. *Transfusion* 1998; 38: 174-176

Fukata S, Kuma K, Sugawara M: Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. *Thyroid* 1999; 9: 29-31

Gardner I, Zahid N, MacCrimmon D, Utrecht JP: A comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes. *Molecular Pharmacology* 1998; 53: 991-998

Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E: Allergic and Autoimmune reactions to xenobiotics: how do they arise? *Immunology Today* 1998; 19(3):133-141

Haas de M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE: Neutrophil Fc- $\gamma$ -Receptor, nature, and clinical consequences: a study of 21 individuals from 14 families. *Blood* 1995; 86: 2403-2413

Hass WK, Easton JD, Adams HP Jr.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. *N Engl J Med* 1989; 321(8):501-7

Heimpel H: Erkrankungen der Leukozyten und Panzytopenien. In: Gerok W, Huber Chr, Meinertz T, Zeidler H, Herausgeber. R. Gross, P. Schölmerich, W. Gerok: Die Innere Medizin, 10. Aufl. Stuttgart: Schattauer, 2000: 170

Hornsten P, Keisu M, Wiholm BE: The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126(7): 919-22

Inohara N, Nunez G: The NOD: a signalling Molecule that regulates apoptosis and host defense against pathogens. Oncogene 2001; 20: 6473-6481

Ibáñez L, Vidal X, Ballarin E, Laporte JR: Population-Based Drug-Induced Agranulocytosis. Archives of Internal Medicine 2005;165: 869-874

Knowles SR, Uetrecht J, Shear NH: Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000; 356: 1587-1591

Janeway CA Jr.: The immune system evolved to discriminate infectious nonself from noninfectious self. Immunology Today 1992; 13: 11-16

Karassa FB, Trikalinos TA, Ioannidis JPA: The Role of Fc-gamma RIIA and IIIA polymorphisms in autoimmune diseases. Biomedicine and Pharmacotherapy 2004;58: 286-291

Keisu M, Wiholm BE, Palmblad J: Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 1990;228(4): 353-60.

van der Kleuw MM, Goudsmit R, Halie R: A population based case-cohort study of drug-associated agranulocytosis. Archives of Internal Medicine 1999;159: 369-375

Lai WG, Zahir N, Uetrecht JP: Metabolism of Trimethoprim to a reactive Iminoquinone Methide by activated human neutrophils and hepatic microsomes. J Pharmacology and Experimental Therapeutics 1999;291(1): 292-299

Landsteiner K, Jacobs J: Studies on the Sensitization of animals with simple chemical compounds. *J Exp Med* 1935;61: 643-656

Lazarou J, Pomeranz BH, Corey PN: Incidence of Adverse Drug Reactions in Hospitalized Patients. *JAMA* 1998;279(15): 1200-1205

Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Goldin LR, Huppi K, Chanock SJ.: Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. *Blood* 1999;94(12): 4220-32

Leppers-van de Straat FGJ, van der Pol WL, Jansen MD, Sugita N et al.: A novel PCR-based method for direct Fc-γ-Receptor IIIa (CD16) allotyping. *J Immunol Methods* 2000; 28: 127-132

Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, Yunis EJ: HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. *Arch Gen Psychiatry* 1990;47(10):945-948.

Liu ZC, Uetrecht JP: Metabolism of Ticlopidine by Activated Neutrophils: Implications for Ticlopidine-induced Agranulocytosis. *Drug Metabolism and Disposition*, 28;7, 2000: 726-730.

Matsuo K, Procter J, Stroncek D: Variations in Genes encoding neutrophil antigens NA1 and NA2. *Transfusion* 2000; 40: 645-653.

Matzinger P: Tolerance, danger, and the extended family. *Annu Rev Immunol* 1994; 12: 991-1045

Matzinger P: The Danger Model: a renewed sense of self. *Science* 2002; 296: 301-305

Miyamoto G, Zahid N, Uetrecht JP: Oxidation of Diclofenac to Reactive Intermediates by Neutrophils, Myeloperoxidase and Hypochlorous Acid 1997;10(4): 414-419

Mosyagin I, Dettling M, Roots I, Mueller-Oerlinghausen B, Cascorbi I.: Impact of myeloperoxidase and NADPH-oxidase polymorphisms in drug-induced agranulocytosis. *J Clin Psychopharmacol* 2004;24(6):613-7

Mosyagin I, Cascorbi I, Schaub R, Krüger T, Dettling M: Drug-induced Agranulocytosis – Impact of different Fc- $\gamma$ -Receptor Polymorphisms? *Journal Clin Psychopharmacol* 2005;25(5): 435- 440

Okamura K, Nakashima T, Ueda K, Inoue K, Omae T, Fujishima M.: Thyroid disorders in the general population of Hisayama Japan, with special reference to prevalence and sex differences. *Int J Epidemiol* 1987;16(4):545-9

Ostrousky O, Meged S, Loewenthal R, Valevski A, Weizman A, Carp H, Gazit E.: NQO2 gene is associated with clozapine-induced agranulocytosis. *Tissue Antigens* 2003; 62(6):483-491

Paradiso-Hardy FL, Angelo CM, Lanctot KL, Cohen EA: Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality. *CMAJ* 2000 Nov 28;163(11):1441-8.

Park BK, Pirmohamed M, Kitteringham NR: Role of Drug Disposition in Drug Hypersensitivity: A chemical, molecular, and clinical perspective. *Chemical Research Toxicol* 1998;11(9): 969-988

Park BK, Kitteringham NR: Drug-protein conjugation and its immunological consequences. *Drug Metab Rev.* 1990;22 (1):87-144

Pirmohamed M, Naisbitt DJ, Gordon F, Park KB: The danger hypothesis – potential role in idiosyncratic drug reactions. *Toxicology* 2002; 181/182: 55-63

Pirmohamed M, James S., Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM: Adverse Drug reactions as cause of admission to hospital: prospective analysis of 18820 patients. *BMJ* 2004;329; 15-19

Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. *Trends in Pharmacological Sciences* 2001;22(6): 298-305

Pohl LR, Satoh H, Christ DD, Kenna JG: The immunologic basis of drug hypersensitivities. *Annu Rev Pharmacol Toxicol.* 1988;28: 367-387

Rekand T, Langeland N, Aarli JA, Vedeler CA: Fc-gamma-Receptor-IIIa polymorphism as a risk factor for acute poliomyelitis. *J Infect Dis* 2002;186(12): 1840-1843

Rote Liste® Buch 2005, Arzneimittelverzeichnis für Deutschland, Rote Liste® Service GmbH.

Salmon JE, Pricop L: Human receptors for Immunglobulin G: key element in the pathogenesis of rheumatic disease. *Arthritis Rheum* 2001;44: 739-750

Schultz, W: Über eigenartige Halserkrankungen. *Dtsch Med Wochenschr* 1922;48: 1495-1497.

Séguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. *Curr Opin Allergy Clin Immunol* 2003;3: 235-242

Shackelford DA, Kaufmann JF, Korman AJ, Strominger JL: HLA-Antigens: structure, separation of subpopulations, gene cloning and function. *Immunol Rev* 1982;66: 133-187

Sprikkelman A, de Wolf JT, Vellenga E: The application of hematopoietic growth factors in drug induced agranulocytosis: a review of 70 cases. *Leukemia* 1994;8: 2031-2036.

Strom BL, Carson JL, Schinnar R, Snyder ES, Shaw M: Descriptive epidemiology of Agranulocytosis. *Archives of Internal Medicine* 1992; 159: 1475-1480

Tajiri J, Noguchi S: Antithyroid Drug-Induced Agranulocytosis: How Has Granulocyte Colony-Stimulating Factor Changed Therapy? *Thyroid* 2005; 15(3): 292-297

Tamai H: Association between the DRB1\*08032 Histocompatibility Antigen and Methimazole-induced Agranulocytosis in Japanese Patients with Graves Disease; *Annals of Internal Medicine* 1996;124(5): 490-494

Taniuchi S, Masuda M, Yamamoto A, Hasui M, Tsuji S, Komiyama Y: Fc RIIIb and Fc RIIa polymorphism may affect the production of specific NA1 autoantibody and clinical course of autoimmune neutropenia of infancy. *Human Immunology* 2001(62): 408-413

Torkildsen O, Utsi E, Mellgren SI, Harbo HF, Vedeler CA, Myhr KM: Ethnic variation of Fc-gamma-Receptor polymorphism in Sami and Norwegian populations. *Immunology* 2005(115): 416-421.

Utrecht JP: The role of leucocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions. *Drug Metabolism Reviews* 1992;24(3): 299-366

Utrecht J: Screening for the potential of a drug candidate to cause idiosyncratic drug reactions. *Drug discovery today* 2003;8(18)

Utrecht JP, Shear NH, Zahid N: N-chlorination of sulfamethoxazole and dapsone by the myeloperoxidase system. *Drug Metab Dispos* 1993;21(5): 830-834.

Weise L: Das Spontanerfassungssystem der AkdÄ und BfArM als Werkzeug weiterführender klinischer Forschung: Eine Analyse am Beispiel Clozapin-induzierter Agranulozytosen. Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Freien Universität, Berlin 2000.

Williams DP, Park BK: Idiosyncratic toxicity: The role of toxicophores and bioactivation. *DDT* 2003;8(22): 1044-1050

Valevski A, Klein T, Gazit E, Meged S, Stein D, Elizur A, Narinsky ER, Kutzuk D, Weizman A.: HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients. *Eur J Immunogenet* 1998;25(1):11-13.

Yuan FF, Wong M, Pererva N, Keating J, Davis AR, Bryant JA, Sullivan JS: Fc-gammaRIIA polymorphisms in *Streptococcus pneumoniae* infection. *Immunology and cell biology* 2003;81: 192-195



Yunis JJ, Lieberman JA, Yunis EJ: Major histocompatibility complex associations with clozapine-induced agranulocytosis. The USA experience. *Drug Safety* 1992;7: 7-9